Eli Lilly has announced its acquisition of Kelonia Therapeutics for $3.25 billion, a move that highlights the biotech company's tumultuous history.
Kelonia Therapeutics, a small player in the biotech sector, has faced significant hurdles in its quest for stability and growth.
This acquisition could signal a new chapter for Kelonia, as it transitions under the umbrella of a larger, more established pharmaceutical entity.